MYOK MyoKardia Inc.

42.93
+0.24  (+1%)
Previous Close 42.69
Open 42.5
Price To Book 4.56
Market Cap 1728781353
Shares 40,270,711
Volume 141,661
Short Ratio
Av. Daily Volume 419,297

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data due 2H 2020.
MYK-461 - EXPLORER-HCM
Hypertrophic cardiomyopathy (HCM)
Phase 2 additional interim data due 1Q 2019.
Mavacamten (MYK-461) - PIONEER-OLE
Non-obstructive Hypertrophic cardiomyopathy (HCM)
Phase 2 top-line data due 2H 2019.
Mavacamten (MYK-461) - MAVERICK-HCM
Hypertrophic cardiomyopathy (HCM)
Phase 2a top-line data due 4Q 2019.
MYK-491
Heart failure

Latest News

  1. Zacks.com featured highlights include: Athene, MyoKardia and Euronav
  2. 3 Earnings Acceleration Stocks You Really Need to Look At
  3. MyoKardia, Inc. (NASDAQ:MYOK) Insiders Have Been Selling
  4. Market Trends Toward New Normal in Duke Energy, VICI Properties, MyoKardia, FLIR, TIER REIT, and ChannelAdvisor — Emerging Consolidated Expectations, Analyst Ratings
  5. MyoKardia Appoints William Fairey as Chief Commercial Officer
  6. Weekly CEO Buys Highlight
  7. Moderna, MyoKardia Are Among Cutting-Edge Biotech Stocks for 2019
  8. MyoKardia to Present at 37th Annual J.P. Morgan Healthcare Conference
  9. Why Tesla, MyoKardia, and Hologic Slumped Today
  10. MyoKardia Regains Global Rights to Mavacamten and MYK-491 Programs from Sanofi
  11. Hedge Funds Are Buying MyoKardia, Inc. (MYOK)
  12. MyoKardia Reports Positive Data from Phase 1b Single-Ascending Dose Clinical Trial of MYK-491 in Dilated Cardiomyopathy and Systolic Heart Failure Patients
  13. MyoKardia to Present at the BMO 2018 Prescriptions for Success Healthcare Conference
  14. Is MyoKardia Inc (NASDAQ:MYOK) As Strong As Its Balance Sheet Indicates?
  15. Consolidated Research: 2018 Summary Expectations for MyoKardia, Bristow Group, The Chefs' Warehouse, Catabasis Pharmaceuticals, Casa, and EP Energy — Fundamental Analysis, Key Performance Indications
  16. Eyeing faster path for sickle cell drug, Peninsula biotech plots expansion — for a higher price
  17. MyoKardia (MYOK) Reports Q3 Loss, Tops Revenue Estimates
  18. MyoKardia: 3Q Earnings Snapshot
  19. All this 500,000-square-foot Berkeley biotech project needs is a developer